Clinical activity and tolerability of SL-401 (Tagraxofusp): Recombinant diphtheria toxin and interleukin-3 in hematologic malignancies

Omar Alkharabsheh, Arthur E Frankel

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Overcoming the leukemia stem cell resistance to intensive chemotherapy has been an area of extensive research over the last two decades. Advances and greater understanding of the molecular biology of leukemia stem cells are in rapid progress. Targeted therapies are currently being used in clinical practice with reasonable response rates, but a cure is being achieved in only a small percentage of patients, most likely due to tumor mutational heterogeneity. A genetically engineered diphtheria toxin fused with interleukin-3 (SL-401 or tagraxofusp) has shown robust activity in blastic plasmacytoid dendritic cell neoplasm and promising response rates in different myeloid malignancies, including eradication of minimal residual disease. Multiple clinical trials are being conducted using this drug and the preliminary results are encouraging. This article reviews the clinical trials for SL-401, its mechanism of action, clinical activity, and the adverse event profile.

Original languageEnglish (US)
Article number6
JournalBiomedicines
Volume7
Issue number1
DOIs
StatePublished - Mar 1 2019
Externally publishedYes

Fingerprint

Diphtheria Toxin
Interleukin-3
Hematologic Neoplasms
Stem cells
Molecular biology
Chemotherapy
Leukemia
Stem Cells
Clinical Trials
Tumors
Neoplasms
Residual Neoplasm
Dendritic Cells
Molecular Biology
Pharmaceutical Preparations
Drug Therapy
Research
Therapeutics

Keywords

  • Adverse events
  • Diphtheria immunotoxin
  • Myeloid neoplasms
  • SL-401 (tagraxofusp)

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Clinical activity and tolerability of SL-401 (Tagraxofusp) : Recombinant diphtheria toxin and interleukin-3 in hematologic malignancies. / Alkharabsheh, Omar; Frankel, Arthur E.

In: Biomedicines, Vol. 7, No. 1, 6, 01.03.2019.

Research output: Contribution to journalReview article

@article{2f425d9c52024ef9bef74e657d7f3c50,
title = "Clinical activity and tolerability of SL-401 (Tagraxofusp): Recombinant diphtheria toxin and interleukin-3 in hematologic malignancies",
abstract = "Overcoming the leukemia stem cell resistance to intensive chemotherapy has been an area of extensive research over the last two decades. Advances and greater understanding of the molecular biology of leukemia stem cells are in rapid progress. Targeted therapies are currently being used in clinical practice with reasonable response rates, but a cure is being achieved in only a small percentage of patients, most likely due to tumor mutational heterogeneity. A genetically engineered diphtheria toxin fused with interleukin-3 (SL-401 or tagraxofusp) has shown robust activity in blastic plasmacytoid dendritic cell neoplasm and promising response rates in different myeloid malignancies, including eradication of minimal residual disease. Multiple clinical trials are being conducted using this drug and the preliminary results are encouraging. This article reviews the clinical trials for SL-401, its mechanism of action, clinical activity, and the adverse event profile.",
keywords = "Adverse events, Diphtheria immunotoxin, Myeloid neoplasms, SL-401 (tagraxofusp)",
author = "Omar Alkharabsheh and Frankel, {Arthur E}",
year = "2019",
month = "3",
day = "1",
doi = "10.3390/biomedicines7010006",
language = "English (US)",
volume = "7",
journal = "Biomedicines",
issn = "2227-9059",
publisher = "MDPI AG",
number = "1",

}

TY - JOUR

T1 - Clinical activity and tolerability of SL-401 (Tagraxofusp)

T2 - Recombinant diphtheria toxin and interleukin-3 in hematologic malignancies

AU - Alkharabsheh, Omar

AU - Frankel, Arthur E

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Overcoming the leukemia stem cell resistance to intensive chemotherapy has been an area of extensive research over the last two decades. Advances and greater understanding of the molecular biology of leukemia stem cells are in rapid progress. Targeted therapies are currently being used in clinical practice with reasonable response rates, but a cure is being achieved in only a small percentage of patients, most likely due to tumor mutational heterogeneity. A genetically engineered diphtheria toxin fused with interleukin-3 (SL-401 or tagraxofusp) has shown robust activity in blastic plasmacytoid dendritic cell neoplasm and promising response rates in different myeloid malignancies, including eradication of minimal residual disease. Multiple clinical trials are being conducted using this drug and the preliminary results are encouraging. This article reviews the clinical trials for SL-401, its mechanism of action, clinical activity, and the adverse event profile.

AB - Overcoming the leukemia stem cell resistance to intensive chemotherapy has been an area of extensive research over the last two decades. Advances and greater understanding of the molecular biology of leukemia stem cells are in rapid progress. Targeted therapies are currently being used in clinical practice with reasonable response rates, but a cure is being achieved in only a small percentage of patients, most likely due to tumor mutational heterogeneity. A genetically engineered diphtheria toxin fused with interleukin-3 (SL-401 or tagraxofusp) has shown robust activity in blastic plasmacytoid dendritic cell neoplasm and promising response rates in different myeloid malignancies, including eradication of minimal residual disease. Multiple clinical trials are being conducted using this drug and the preliminary results are encouraging. This article reviews the clinical trials for SL-401, its mechanism of action, clinical activity, and the adverse event profile.

KW - Adverse events

KW - Diphtheria immunotoxin

KW - Myeloid neoplasms

KW - SL-401 (tagraxofusp)

UR - http://www.scopus.com/inward/record.url?scp=85063585546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063585546&partnerID=8YFLogxK

U2 - 10.3390/biomedicines7010006

DO - 10.3390/biomedicines7010006

M3 - Review article

C2 - 30621282

AN - SCOPUS:85063585546

VL - 7

JO - Biomedicines

JF - Biomedicines

SN - 2227-9059

IS - 1

M1 - 6

ER -